Showing 4951-4960 of 9773 results for "".
- Starton Secures New Patent for Transdermal Lenalidomide Deliveryhttps://practicaldermatology.com/news/starton-secures-new-patent-transdermal-lenalidomide-delivery/2468506/Starton Therapeutics announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its STAR-LLD transdermal drug delivery patent application, providing potential extended patent protection through 2040. According to a press release, the development broad
- Deuruxolitinib Shows Efficacy in Adults with Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-shows-efficacy-adults-severe-alopecia-areata/2468485/New findings on LEQSELVI™ (deuruxolitinib) presented at the 44th Annual Fall Clinical Dermatology Conference showed sustained efficacy and safety in adults with severe alopecia areata (AA). According to a press release from the manufacturer, the FDA-approved JAK inhibitor showed meaningfu
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- ADORING 3: Tapinarof Cream Maintains AD Clearance for 80 Days Post-Treatmenthttps://practicaldermatology.com/news/adoring-3-tapinarof-cream-maintains-ad-clearance-80-days-post-treatment/2468482/Results from the ADORING 3 long-term extension study showed that VTAMA® (tapinarof) cream, 1% achieved complete skin clearance in atopic dermatitis (AD) patients as young as two years old, maintaining clear or nearly clear skin for an average of 80 days post-treatment. The 48-week study, p
- Study Backs CP-GEP Tests’ Accuracyhttps://practicaldermatology.com/news/study-backs-cp-gep-tests-accuracy/2468469/Patients with clinically node-negative primary cutaneous melanoma undergoing sentinel lymph node biopsies (SLNBs) who were classified as “high risk” according to CP-GEP tests were approximately three times more likely to be SLN positive, according to data presented October 13 at the Society of Me
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://practicaldermatology.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2468433/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. The goal of the rebrand is
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter
- Study Analyzes Metabolites and ADhttps://practicaldermatology.com/news/study-analyzes-metabolites-and-ad/2468384/Bidirectional two-sample Mendelian randomization (MR) analyses in a study published in Scientific Reports indicated that 22 metabolites and one inflammatory protein (S100A12) were significantly associated with atopic dermatitis (AD) pathogenesis. “The levels of amino acid metaboli